Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer
The efficacy and safety of the use of Camrelizumab combined with Apatinib
Colorectal Cancer Recurrent
DRUG: Camrelizumab|DRUG: Apatinib
Objective response rate, Objective response rate (ORR) according to Response Evaluation Criteria in Solid Tumours (RECIST) version. 1.1, and immune-related (ir) RECIST, one year
Incidence of Treatment-Emergent Adverse-Events, Incidence of adverse events, one year
To evaluate the clinical efficacy and safety of Camrelizumab combined with Apatinib in the treatment of patients with advanced gastric cancer and colorectal cancer.

The 62 patients were enrolled in a 2-week regimen with 200mg Camrelizumab given intravenously every two weeks and 250mg apatinib mesylate every 4 weeks for a treatment cycle until progressive or intolerableï¼Œthen the objective remission rate(ORR) was calculated.